IQVIA's (IQV) "Buy" Rating Reaffirmed at Truist Financial

IQVIA (NYSE:IQV - Get Free Report)'s stock had its "buy" rating restated by investment analysts at Truist Financial in a research note issued on Monday,Benzinga reports. They presently have a $263.00 price target on the medical research company's stock, up from their previous price target of $261.00. Truist Financial's price objective suggests a potential upside of 33.67% from the company's previous close.

Several other equities research analysts have also recently weighed in on IQV. Royal Bank of Canada restated an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Finally, TD Cowen decreased their price target on IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $251.67.

IQVIA Price Performance

Shares of NYSE IQV traded down $1.06 during mid-day trading on Monday, hitting $196.76. 497,502 shares of the stock were exchanged, compared to its average volume of 1,379,656. The company has a market cap of $35.71 billion, a P/E ratio of 26.23, a PEG ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The stock's fifty day simple moving average is $200.66 and its two-hundred day simple moving average is $218.67.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts forecast that IQVIA will post 10.81 EPS for the current fiscal year.

Insider Activity

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the business's stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company's stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the third quarter worth $27,000. Avior Wealth Management LLC increased its holdings in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after purchasing an additional 87 shares in the last quarter. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at about $33,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA in the fourth quarter valued at about $44,000. Finally, Assetmark Inc. boosted its position in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after buying an additional 196 shares during the period. Institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.